Benitec Q1 net loss $9.0M; BB-301 100% responder rate; FDA Fast Track; raised $100M

Benitec Biopharma Inc.

2026-Q1 EPS reported -$0.22 vs consensus -$0.28 ▲ beat (+21.2%)

Net loss of $9.0M ($0.22/sh) vs $5.1M ($0.18) YoY; total expenses $9.8M, up from $5.8M.
All 6 Cohort 1 patients in BB-301 Phase 1b/2a met formal response criteria (100% responder rate).
FDA granted Fast Track Designation for BB-301; first Cohort 2 patient dosed in Q4 2025.
Raised ~$100M in oversubscribed equity offering at $13.50/sh; cash $94.5M at Sep 30.
Appointed Sharon Mates (ex-CEO Intra-Cellular Therapies) to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.